Business Wire

Axonics® Announces Publication of NICE Briefing

Jaa

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today the publication of a Medtech Innovation Briefing by The National Institute for Health and Care Excellence (“NICE”) following a careful review of the innovations offered by the Axonics System.

The NICE Medtech Innovation Briefing entitled: “Axonics rechargeable sacral neuromodulation system for overactive bladder and faecal incontinence,” describes published clinical evidence on the Axonics r-SNM System®, confirming efficacy as well as the potential positive economic impact that is possible by the use of the Axonics system in the United Kingdom.

The Axonics r-SNM System is the first rechargeable Sacral Neuromodulation system approved for sale in Europe and commercially available to all hospitals and clinics in the U.K. for patients suffering from urinary and fecal dysfunction. It is estimated that approximately 1,200 patients receive a Sacral Neuromodulation implant in the U.K. every year.

Raymond W. Cohen, CEO of Axonics, commented, “NICE is a highly rigorous and respected institution, and we are proud that the Axonics system is recognized as an innovative technology deserving attention from the U.K. physician community. This publication is a testimony to the ingenuity of our engineering, regulatory and quality teams, as well as our focus on providing a solid foundation of clinical evidence.”

The NICE Briefing can be found here: https://www.nice.org.uk/advice/mib164

About The National Institute for Health and Care Excellence (NICE)
NICE provides guidance and advice to improve health and social care primarily in England. NICE is accountable to the UK’s Department of Health and Social Care, however, is operationally independent of government. Guidance and other recommendations are made by independent committees. NICE was originally set up in 1999 as the National Institute for Clinical Excellence, a special health authority, to reduce variation in the availability and quality of NHS treatments and care. In 2005, after merging with the Health Development Agency, NICE began developing public health guidance to help prevent ill health and promote healthier lifestyles and the name changed to the National Institute for Health and Clinical Excellence. In April 2013 we were established in primary legislation as set out in the Health and Social Care Act 2012 and became a Non-Departmental Public Body (NDPB) taking on responsibility for developing guidance and quality standards in social care, and our name changed once more to reflect these new responsibilities.

About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, is focused on development and commercialization of novel implantable Sacral Neuromodulation devices for patients with urinary and bowel dysfunction. Overactive bladder affects an estimated 85 million adults in the U.S. and Europe. Another approximately 40 million adults are reported to suffer from fecal incontinence. SNM therapy is well-established treatment that has been widely used and reimbursed in Europe and the U.S. for the past two decades. The Axonics r-SNM System is the first rechargeable Sacral Neuromodulation system approved for sale in Europe, Canada and Australia. The r-SNM System offers a temporary disposable external trial system, a miniaturized and rechargeable long-lived stimulator that is designed and qualified to function for at least 15 years. Also included is a tined lead, as well as patient-friendly accessories such as a charging system optimized for minimal charge time without overheating, a small, easy to use patient remote control and an intuitive clinician programmer that facilitates lead placement and programming. For more information, visit the Company’s website at www.axonicsmodulation.com.

Forward-Looking Statements
Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as “planned,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

Contact information

Axonics’ Contact
Axonics Modulation Technologies, Inc.
Dan Dearen, +1-949-396-6320
President & Chief Financial Officer
ir@axonics.com

Investor & Media Contact
W2Opure
Matt Clawson, +1-949-370-8500
mclawson@w2ogroup.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Enamine Extends Multi-Year Drug Discovery Collaboration with Lundbeck26.3.2019 12:17:00 EETTiedote

Enamine Ltd. a provider of integrated drug discovery services empowered by the world’s largest collections of building blocks and screening compounds, and H. Lundbeck A/S (Lundbeck), the global pharmaceutical company involved in the research of new drugs for the treatment of disorders in the central nervous system, today announced the expansion of their research collaboration. Enamine will support Lundbeck’s in-house discovery chemistry competencies with three principal assets enabling Lundbeck to optimally identify and develop hit series in its multiple research programs. A large diverse library of 100,000 new screening compounds for hit finding activities on numerous therapeutic targets. Enamine’s make-on-demand REAL compounds (Nature, 2019, Vol. 566, p. 224–229) for efficient access to billions of novel chemical compounds. An increased dedicated team of Enamine FTE chemists to effectively support Lundbeck on all hit related follow-up activities backed by immediate access to over 170

Acuris Risk Intelligence launches Acuris Cybercheck26.3.2019 12:00:00 EETTiedote

Acuris Risk Intelligence, a trusted and independent provider of data intelligence for anti-money laundering, anti-corruption and cyber security professionals, today announces the launch of Acuris Cybercheck, a database that allows businesses and individuals to identify whether or not their information has been compromised by criminals. Acuris Cybercheck provides the largest proprietary database of compromised personal ID data. Complied since 2008, the database includes information traded on criminal websites globally such as identity, personal and financial data. It also allows users to search via APIs against specific records or to continuously monitor data. The database is a one-stop shop for monitoring compromised data, allowing users to, among other things, proactively monitor personal data and receive alerts, mitigate identified risks, improve GDPR compliance, provide evidence of potential data breach and assess data compromise in M&A and corporate transactions. The system uses sk

GlobalLogic Appoints Veteran CEO Björn Ivroth as Board Advisor26.3.2019 11:00:00 EETTiedote

GlobalLogic Inc., a leader in digital product engineering, today announced that, effective immediately, Björn Ivroth joins the company as an advisor to its Board of Directors. Mr. Ivroth recently served as the CEO of EVRY, a leading Nordic IT services and software provider. In this role, he will work alongside the Board, the CEO, and fellow accomplished leaders contributing to the development and execution of growth strategies driving GlobalLogic’s European business. “We are thrilled to have someone of Björn’s caliber as part of our advisory team,” said Shashank Samant, CEO, GlobalLogic. “His experience as an operating leader, and deep knowledge of the European market are tremendous assets to GlobalLogic, and we are looking forward to leveraging his expertise as we continue to expand our European footprint.” Mr. Ivroth started his career as a Management Consultant at McKinsey & Company. Other early experiences include leadership roles focused on IT Services at Accenture and IBM. His ca

European MSPs Could Lose SMB Clients Over Cybersecurity: Vanson Bourne Report26.3.2019 11:00:00 EETTiedote

Cybersecurity demands of small- and medium-sized businesses (SMBs) have become both a major risk and revenue opportunity to managed service providers (MSPs). This is according to research conducted by Vanson Bourne and commissioned by Continuum ®, the proactive platform that integrates intelligent software with expert services for MSPs to scale dynamically and protect their clients. Underserved and Unprepared: The State of SMB Cyber Security in 2019, released today, draws on data collected in 2019 from 850 SMBs across the United States, United Kingdom, France, Germany and Belgium. In addition to the risks for MSPs, the report also highlights the significant revenue opportunity for providers that deliver the cybersecurity services and solutions SMBs need to protect their businesses. Vanson Bourne’s research in the four European countries found that MSPs are at risk of losing their SMB clients over cybersecurity concerns. More than nine in ten (93 percent) SMBs would consider hiring a ne

Evaluate Ltd. Appoints Deborah Kobewka as Chief Executive Officer26.3.2019 11:00:00 EETTiedote

Evaluate Ltd., the leading provider of commercial data to the life sciences industry, is pleased to announce the appointment of Deborah Kobewka as Chief Executive Officer, effective immediately. Deborah succeeds Alex Karle, who joined Evaluate in 2012 as Chief Operating Officer before assuming the role of CEO in 2014. Deborah brings to Evaluate over 30 years of expertise in the global pharmaceutical, healthcare and information sectors. With her successful track record of driving commercial expansion, she is well positioned to accelerate the company’s current growth trajectory. Deborah joins Evaluate from the Department for International Trade in the UK government where she served as Managing Director of Healthcare UK, Lifesciences and Bio-economy. Prior to that, she held senior corporate and operational roles at both private and government organisations in the UK, Europe and Asia, including 24 years at IMS Health (now IQVIA). “Evaluate has an impressive history of pioneering solutions

Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues26.3.2019 09:00:00 EETTiedote

Illumina (NASDAQ:ILMN) and the Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark partner to explore the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens. One of the first projects of its kind worldwide, the endeavor aims to acquire new knowledge in terms of the medical and biological understanding of special factors underlying the development of human neuropsychiatric diseases through the ages. Ultimately, the project may provide a new approach to the development of medicines and other therapeutic treatments for mental and neurological conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005867/en/ Where do brain disorders come from? In an effort to shed light on the role of microbes in the pathogenesis of neuropsychiatric illnesses, such as Alzheimer’s disease and schizophrenia, Professor Eske Willerslev and his team

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme